Thus, MTC-22 could be used to investigate mechanisms underlying ovarian clear cell carcinoma, particularly cases with PIK3CB mutations, or to validate new diagnostic and therapeutic approaches for this type of cancer. Here, PIK3CB is linked to cancer.